= Solution
\b[Susceptibility of an isolated bacterium and failure to clear an infection measure different things.] The scenario does not establish a particular resistance gene or a real species-specific mechanism. First distinguish <antibiotic resistance>, an increased ability to grow at inhibitory drug <concentrations>, from <antibiotic tolerance>, slower killing without the corresponding increase in the growth-inhibiting <concentration>, and <bacterial persistence>, survival of a subpopulation in an otherwise susceptible population.
One explanation is a reversible physiological state. Slowly growing or metabolically altered <bacteria> can survive an <antibiotic> whose lethal action depends on the active process it targets. Regrown survivors can then recover the original susceptibility. <Nathalie Q. Balaban> and colleagues directly followed individual <bacteria> and showed switching between growth states associated with persistence. The important inference is phenotypic heterogeneity, not that all survivors must share one dormant state or one toxin-antitoxin pathway.<Bacterial persistence as a phenotypic switch by Nathalie Q. Balaban and others>[Single-cell observations and susceptibility after regrowth]{ref}
A second explanation is the local infection environment. <Biofilms> can generate heterogeneous growth conditions, altered penetration and protected reservoirs; intracellular localization can separate <bacteria> from otherwise adequate extracellular drug exposure. Nutrient limitation, oxygen conditions, pH and host stress can change physiology or drug activity. Conversely, a laboratory sample may miss a resistant minority, mixed infection or an inducible <phenotype>, so apparent susceptibility should not be treated as proof that every bacterium at every site has the same response.
Triggers can include changes imposed by the host environment, entry into a slow-growth state, or stress associated with prior exposure. These are alternative hypotheses: the question supplies no data selecting one. <Bacteria> surviving because exposure never reached an effective level are also different from <bacteria> surviving an adequately delivered exposure. Persistence may pre-exist exposure rather than being induced by it.
At the level of investigation, compare inhibition of growth with survival over time, examine whether the <phenotype> persists after regrowth, and assess population heterogeneity and protected infection sites. A high-level response to treatment failure is to identify the reservoir and exposure problem, establish which organism and <phenotype> are actually present, and consider approaches addressing that mechanism rather than assuming that simply increasing the same drug will solve it. Removal of a colonized foreign-body reservoir, where relevant, addresses a different cause from a change in antimicrobial choice. The information supplied is insufficient to name an effective drug regimen or infer a single molecular trigger.
Back to article page
